AbbVie's oncology sales climbed 4.2% in H1 2025 as new drugs offset Imbruvica declines, strengthening its long-term growth outlook.

Oncology sales comprise more than 25% of Pfizer’s total revenues. Its oncology revenues grew 9% in the first half of 2025, ...

Roche has found redemption in a precision medicine approach following an earlier Tecentriq trial flop in a broader bladder cancer population. | Roche has found redemption in a precision medicine ...

PD-1 inhibitors are projected to dominate future drug sales. Immuno-oncology therapies, particularly the PD-(L)1 class, have revolutionized cancer ca ...

AZ and Daiichi Sankyo are running trials of Datroway in combination with AZ's PD-L1 inhibitor Imfinzi (durvalumab) in TNBC, including TROPION-Breast04, a study looking at adjuvant therapy, and ...

A medical crisis is reshaping the cancer treatment landscape. Young adults under 50 are experiencing unprecedented cancer rates, with aggressive tumors requiring innovative combination approaches that ...